Acquired von Willebrand syndrome secondary to Waldenström’s macroglobulinemia

Satoko Hijii¹, Taiichi Kodaka¹, Takae Goka², Yumi Aoyama¹, Hiroko Tsunemine¹, Takayuki Takahashi*¹

¹Department of Hematology, Shinko Hospital, Kobe, Japan
²Department of Laboratory Medicine, Shinko Hospital, Kobe, Japan

Received: March 25, 2019  Accepted: June 18, 2019  Online Published: July 18, 2019
DOI: 10.5430/crim.v6n3p13  URL: https://doi.org/10.5430/crim.v6n3p13

ABSTRACT

Acquired von Willebrand (vW) syndrome in Waldenström’s macroglobulinemia (WM) should be differentially diagnosed from hyperviscosity syndrome of WM, which exhibits a bleeding tendency. We report a rare case of acquired vW syndrome secondary to WM. A 62-year-old woman was referred to our hospital because of extensive subcutaneous hemorrhage following a light hit to the left arm. Although the platelet count was normal, APTT was prolonged to 49.4 sec. Furthermore, the serum concentration of IgM was elevated to 7,796 mg/dL, which was revealed to be IgM-κ monoclonal protein, leading to a diagnosis of WM. On ophthalmofundoscopy, mild hemorrhage, but not retinal vein dilatation, was observed. Regarding the abnormal APTT value, we measured coagulation factors in the intrinsic arm, revealing reduced activities of vW factor and factor VIII of 11 and 18%, respectively. Furthermore, the amount of vW protein was decreased to 23%. Multimer analysis of vW factor demonstrated an abnormal pattern lacking high-molecular-weight bands. Additional diagnosis of acquired vW syndrome secondary to WM was made. The APTT cross-mixing test showed a simple but not inhibitor-related decreasing pattern of vW factor, suggesting the absorption of this factor by abnormal lymphoplasmacytic cells. The patient was treated with bendamustine, leading to reduced IgM, improvement of the APTT value, and the normal multimer pattern of vW factor.

Key Words: Acquired von Willebrand syndrome, Waldenström’s macroglobulinemia, Multimer analysis of von Willebrand factor, APTT cross-mixing test

1. INTRODUCTION

Acquired von Willebrand (vW) syndrome is a rare bleeding disorder with clinical and laboratory findings similar to those of congenital vW disease.⁴⁻⁻³ Regarding the underlying disease of acquired vW syndrome, a large cohort of this disorder included lymphoproliferative (48%), cardiovascular (21%), myeloproliferative (15%), neoplasia (5%), immunological (2%), and miscellaneous (9%) disorders.⁴⁻⁻⁵

As for the cause of decreasing vW factor, a number of pathogenic mechanisms have been reported, including IgG or IgM autoantibodies to vW factor,⁵ increasing vW factor clearance from plasma,⁶ absorption of vW factor by tumor cells,⁷⁻⁸ proteolytic cleavage of vW factor after shear stress caused by turbulent blood flow in cardiac valvular disease or cardiac device assistance,⁹⁻¹⁰ and decreased synthesis of normal vW factor (in hypothyroidism).¹¹ The absorption mechanism has attracted attention in recent years in essential thrombocythemia (ET), in which excess numbers of platelet absorb vW factor resulting in a bleeding tendency.¹² In vW syndrome in ET, platelet-derived microparticles or endothelial modulators such as nitric oxide, adenomedullin, or endothelin-1 may be involved in the pathogenesis.¹³ Here, we report a rare case of acquired vW syndrome secondary to
Waldenström’s macroglobulinemia (WM), in which absorption of vW factor by lymphoplasmacytic cells was suggested.

2. CASE PRESENTATION

A 62-year-old female was referred and admitted to our hospital in October 2015 because of extensive subcutaneous hemorrhage following a light hit to the left arm, prolonged activated partial thrombin time (APTT) (49.4 seconds), and high serum concentration of IgM (7,796 mg/dl). As for her medical history, she had hypertension but not bleeding disorder. No bleeding disorders were present in her family or relatives.

Physically, the hemorrhage in the left arm improved because of the time lag from the onset of hemorrhage. On ophthalmoscopy, mild hemorrhage, but not retinal dilatation or a choked disk, was observed. Neither superficial lymphadenopathy nor hepatosplenomegaly was noted.

Laboratory findings on admission are shown in Table 1. The white cell count (WBC) was 4.9 × 10⁹/L with a normal differential count, the hemoglobin concentration was 8.8 g/dl, and platelet count was 169 × 10⁹/L. A hemostat test showed prolonged APTT of 49.4 seconds (normally 25 to 35 seconds). The serum concentration of IgM was 7,700 mg/dl, and serum electrophoresis showed an M-peak that was revealed to be IgM-κ type M protein by immunofixation. A bone marrow aspirate showed a number of lymphoplasmacytic cells, which comprised 15.6% of nucleated cells. These cells were positive for CD19, CD20, smIgM, smκ, cyIgM, and cyκ but negative for CD56, CD138, smλ and cyλ. From these results, a diagnosis of WM was made.

Table 1. Laboratory data on admission

<table>
<thead>
<tr>
<th>Hematology</th>
<th>Serology</th>
<th>Hemostasis</th>
<th>Chemistry</th>
<th>Urinalysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>RBC 2,980×10⁹/L</td>
<td>CRP 0.01 mg/dl</td>
<td>PT(%) 61%</td>
<td>AST 13 U/L</td>
<td>GLU (-)</td>
</tr>
<tr>
<td>Hb 8.8 g/dl</td>
<td>TP 11.2 g/dl</td>
<td>PT-INR 1.25</td>
<td>ALT 5 U/L</td>
<td>PRO (+)</td>
</tr>
<tr>
<td>Ht 27.9%</td>
<td>A/G 0.4</td>
<td>APTT 49.4 sec</td>
<td>ALP 177 U/L</td>
<td>BL (+)</td>
</tr>
<tr>
<td>PLT 169×10⁹/L</td>
<td>ALB 40.8%</td>
<td>FIB 168 mg/dl</td>
<td>T.Bil 0.8 mg/dl</td>
<td>BIL (-)</td>
</tr>
<tr>
<td>WBC 4.9×10⁹/L</td>
<td>a1 1.7%</td>
<td>D-dimer 0.5 μg/ml</td>
<td>γGTP 10 U/L</td>
<td>URO (+)</td>
</tr>
<tr>
<td>Neut 71.6%</td>
<td>a2 4.8%</td>
<td></td>
<td>ChE 268 U/L</td>
<td></td>
</tr>
<tr>
<td>Eos 0.4%</td>
<td>β 4.9%</td>
<td></td>
<td>LDH 102 U/L</td>
<td></td>
</tr>
<tr>
<td>Bas 0.4%</td>
<td>γ 47.8%</td>
<td></td>
<td>CK 80 U/L</td>
<td></td>
</tr>
<tr>
<td>Mon 4.8%</td>
<td>IgA 26 mg/dl</td>
<td></td>
<td>AMY 102 U/L</td>
<td></td>
</tr>
<tr>
<td>Lym 22.0%</td>
<td>IgG 290 mg/dl</td>
<td></td>
<td>BUN 12.4 mg/dl</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IgM 7,700 mg/dl</td>
<td></td>
<td>CRE 0.70 mg/dl</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>UA 5.2 mg/dl</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Na 138 mEq/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>K 4.0 mEq/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cl 102 mEq/L</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ca 9.5 mg/dl</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>T-CHO 93 mg/dl</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TG 56 mg/dl</td>
<td></td>
</tr>
</tbody>
</table>

Note: The normal limits of APTT, IgM, and IgG were 25 to 35 seconds, 46 to 260 mg/dl, and 870 to 1,700 mg/dl, respectively.

Because APTT was prolonged to 49.4 seconds, further examinations regarding coagulation factors in the intrinsic arm were performed, revealing reduced activities of vW factor and factor VIII of 11 and 18%, respectively. Furthermore, the amount of vW protein (rate of normal value) was decreased to 23%. Other coagulation factors including IX, X, XI, and XII factors were all within normal limits. Multimer analysis of vW factor² demonstrated an abnormal pattern lacking high-molecular-weight bands (see Figure 1). The APTT cross-mixing test¹ demonstrated a downward convex pattern in both immediate and prolonged APTT assays (see Figure 2), suggesting a decreased amount of vW factor but not an inhibitor-related decreasing pattern of vW factor. An additional diagnosis of acquired vW syndrome was made.

WM of the present patient was treated with bendamustine; after 2 courses of this chemotherapy, the serum concentration of IgM was decreased to 3,342 mg/dl and APTT was normalized with a value of 36.6 seconds. The activities of vW factor and factor VIII, and the amount of vW protein (rate of normal value) were also improved to 42%, 58%, and 57%, respectively. The patient has since been periodically treated with retuximab, with serum IgM levels of around 3,000 mg/dl, a normal APTT value, and no bleeding tendency as of March 2019.
Figure 1. Multimer analysis of von Willebrand factor before and after chemotherapy for underlying Waldenstöm’s macroglobulinemia. N: Normal multimer pattern from a healthy person. P (Nov. 2015): Multimer pattern from the present patient before chemotherapy. Characteristic distorted bands of low-molecular-weight factors were seen, and bands of high-molecular-weight factors were lost. P (Oct. 2016): Multimer pattern from the patient after chemotherapy. Almost the same pattern was seen when compared with the control (N).

3. DISCUSSION

In the present patient, hyperviscosity syndrome\cite{17, 18} should be ruled out because the serum concentration of IgM was as high as 7,700 mg/dl. However, neither retinal vein dilatation nor a choked disk was observed on ophthalmofundoscopy; therefore, mild retinal bleeding may have been attributable to acquired vW syndrome.

Regarding the incidence of the association of WM and acquired vW syndrome, to the best of our knowledge, 50 cases of acquired vW syndrome in WM patients have been reported in the literature.\cite{6, 19–35} Acquired vW syndrome in WM patients, therefore, may be rare, because WM is a relatively common disease. Hivert et al., however, reported that 10 patients fulfilled the criteria for acquired vW among 72 consecutive patients with WM.\cite{29} On the other hand, Kumar et al. described only 3 cases of WM among 20 cases of acquired vW syndrome in a single institution.\cite{27} Therefore, the exact incidence of acquired vW syndrome in WM is still to be clarified. Furthermore, the possibility of acquired vW syndrome should be taken into consideration even if the bleeding tendency has been tentatively attributed to hyperviscosity syndrome.\cite{17, 18} In this situation, a screening test for APTT may be important.

Figure 2. The APTT cross-mixing test before chemotherapy. The prolonged APTT of the patient’s plasma was compensated by increasing concentrations of normal plasma showing a downward convex pattern in both immediate and prolonged APTT assays. For the prolonged APTT test, respective plasma specimens were incubated at 37°C for 120 min, and then APTT was measured.

As for the pathogenic mechanism of acquired vW syndrome in 50 reported WM patients, a number of mechanisms have been identified or suspected; first, IgG antibody against vW factor;\cite{19} second, some antibody against vW factor;\cite{25} third, possible IgM antibody against vW factor/dysfunction of vW by IgM paraprotein.\cite{31, 33} Two cases in which plasmaphere-
sis caused the remission of acquired vW syndrome might be classified into this category.\cite{20, 21} The absorption of vW factor by tumor cells,\cite{17, 8} as suggested in the present patient, was not described in these 50 patients with WM complicated by acquired vW syndrome. Similarly, the pathogenic mechanism of acquired vW syndrome was not examined or
described in the majority of these 50 cases. We summarized the above identified or suspected pathogenic mechanisms of acquired vW syndrome in WM patients in Table 2.

Table 2. Identified or suspected pathogenic mechanisms of acquired vW syndrome in WM patients

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>IgG antibody against vW factor</td>
<td>yes</td>
<td>no</td>
<td>19</td>
</tr>
<tr>
<td>IgM antibody against vW factor</td>
<td>no</td>
<td>yes</td>
<td>31</td>
</tr>
<tr>
<td>Some antibody against vW factor</td>
<td>no</td>
<td>yes</td>
<td>25</td>
</tr>
<tr>
<td>Dysfunction of vW factor by IgM paraprotein</td>
<td>no</td>
<td>yes</td>
<td>20, 21, 33</td>
</tr>
<tr>
<td>Absorption of vW factor by lymphoplasmacytic tumor cells</td>
<td>no</td>
<td>yes</td>
<td>Present case</td>
</tr>
</tbody>
</table>

Note: vW: von Willebrand; WM: Waldenström’s Macroglobulinemia.

In conclusion, acquired vW syndrome should be taken into consideration when a WM patient presents with a bleeding tendency even when hyperviscosity syndrome is suspected. In such a situation, screening tests of coagulation factors in the intrinsic arm, as well as APTT, are important.

ACKNOWLEDGEMENTS
The authors are grateful to Miss Mizue Higashi for her excellent support for manuscript preparation and literature search.

CONFLICTS OF INTEREST
The author declares no conflict of interest.

REFERENCES


